Advanced searches left 3/3

Carcinoma Esophagus - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 19 November 2022

* If you want to update the article please login/register

Early Detection of Esophageal Cancer

Esophageal squamous cell carcinoma is a leading cause of death in the central Asian esophageal cancer belt, and human papillomavirus has been described as a potential cause. Given the potential for cancer prevention by using the vaccine if HPV is involved, it is imperative to determine whether HPV is or is not involved in ESCC in Linxian given the possibility of cancer prevention by using the vaccine. We will one determine the prevalence of HPV DNA in ESCC tumors and two other cases analyze HPV DNA in HPV DNA-positive cases. HPV DNA will also be tested for the presence of HPV DNA in Nontumor specimens, while serum sera will be tested for HPV 16 and HPV 18 E6/E7 seropositivity as a predictor of HPV-associated cancer.

Source link: https://clinicaltrials.gov/ct2/show/NCT00341523


Esophageal cAncer Screening Trial (EAST) Based on Novel Sponge Cytology:a Multicenter Nationwide Study

Esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer-related deaths globally in 2020. Although esophageal adenocarcinoma of the esophagogastric junction, the esophageal cancer of the esophagogastric junction was less common in these high-risk areas, but it accounts for approximately two-thirds of esophageal cancer cases in Europe and North America, according to the European and North American figures. In China, 57. 5 percent of global ESCC cases and 60% of cardiac gastric cancer cases were projected, with 60. 8% of cardiac gastric cancer cases in 2018. The majority of esophageal cancer high-risk areas are located in developing countries with limited medical facilities, high incidence, and co-occurrence of ESCC and AEG, which have posed significant challenges for disease prevention. Upper gastrointestinal endoscopy in Lugol's staining may increase the early detection rate and reduced both the incidence and mortality of ESCC and AEG in high-risk areas, according to population-based studies in China. The esophageal sponge cytology is a new, minimally invasive, and cost-effective test for esophageal cancer, as well as its precancerous lesions and conditions. The Cytosponge-trefoil factor 3 in Barrett esophagus is a non-endoscopic examination that can raise the risk of BE for 10. 6 percent in patients with reflux disease in the primary care setting, and it could raise the likelihood of BE for 10. 6 percent. Therefore, we undertook the Esophageal cAncer Screening Trial to identify and validate a fully automated machine learning scheme based on cytological and epidemiological data for ESCC and AEG screening in high-risk areas.

Source link: https://clinicaltrials.gov/ct2/show/NCT04609813


The Golestan Cohort Study of Esophageal Cancer

Esophageal cancer is the sixth most common cause of cancer death worldwide, killing over 380,000 people each year. Over 80% of esophageal cancers occur in developing countries, where the overwhelming majority of cases are squamous cell carcinomas. Esophageal cancer is characterized by a regional variation in incidence. Both genders have high incidence rates in Central Asia and northern China, one of the Central Asian Esophageal Cancer Belt, stretches from the Caspian Sea to northern China and includes key areas with reported incidence rates greater than 90% in both genders. D CEG investigators have investigated esophageal and gastric cancer in Linxian, China, one of China's most high-risk areas, for the past 20 years. While these studies have found new risk factors for esophageal cancer in this area, they have left an incomplete picture of the disease's etiology. Golestan's people are geographically, socioeconomically, and ethnically quite different from Linxian's people, and they seem to be unremarkably high in esophageal cancer incidences. Both countries have similar populations, so doing similar studies in these two exceptional populations could provide us with a greater chance to identify important new modifiable risk factors for esophageal cancer. Our cohort study is a joint effort between the Digestive Disease Research Center of Tehran University of Medical Sciences, the International Agency for Research on Cancer, and DCEG. In three administrative districts of eastern Golestan Province, the study has recruited 50,000 adults.

Source link: https://clinicaltrials.gov/ct2/show/NCT00450788


The Registry Study of Genetic Alterations of Esophageal Cancer in Taiwan

Esophageal squamous cell carcinoma, a common histological disease of esophageal cancer in Asia, including Taiwan, has distinct epidemiological, laboratory, and pathological characteristics from esophageal adenocarcinoma, which is also seen in Western countries. In Taiwan, esophageal cancer has ranked as one of the top cause of cancer-related deaths for decades. Patients with locally advanced ESCC are often treated with chemotherapy and surgery, but more than half of them will eventually experience disease recurrence or distant metastasis. In Taiwan, a trend of increasing incidence of youth mortality has been present. The investigators found that elderly ESCC patients with systemic chemotherapy may have better prognosis than younger patients in one of our previous studies focusing on the prognosis of metastatic or recurrent ESCC patients treated with systemic chemotherapy. In addition, the preliminary results of our latest studies reveal that the genetic variations of ESCC in patients of various age groups may be different. The investigators also suggested this multi-center research initiative to answer the fore-mentioned questions by gathering tumor tissue from ESCC patients for next-generation sequencing analysis with a panel of cancer-related genes, as well as developing a platform for data storage and sharing. The primary objectives of this research are to establish the tumor genetic and molecular profiles of ESCC patients in Taiwan, to compare the genetic and molecular profiles of various age groups of ESCC patients, and to determine the transition of genetic and molecular profiles of ESCC patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04996095


A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer

Since both proton and photon therapies are biologically similar, the researchers do not expect a difference in tumor control when compared to intensity modulated radiation therapy. The investigators also have a prospective history of physician-reported toxicity and patient outcomes using IMRT for patients with inoperable esophagus cancer, which will serve as a comparison group.

Source link: https://clinicaltrials.gov/ct2/show/NCT03482791

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions